MeiraGTx (MGTX) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MeiraGTx (MGTX) has outperformed Sana Biotechnology (SANA) over the past year, gaining 22.0% versus a loss of 37.3%. Over five years, MGTX leads with a -26.5% price change compared with -86.6% for SANA. MeiraGTx is the larger company by market cap ($1.03 billion vs $835.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGTX | SANA |
|---|---|---|
| Share price | $10.69 | $2.79 |
| Market cap | $1.03B | $835.22M |
| 1-day change | +1.81% | 0.00% |
| YTD return | +34.47% | -31.45% |
| 1-year return | +22.03% | -37.30% |
| 5-year return | -26.47% | -86.58% |
| P/E ratio (TTM) | 12.29 | — |
| EPS (TTM) | $0.87 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.35 | $6.55 |
| 52-week low | $6.62 | $2.61 |
| Distance from 52-week high | -30.36% | -57.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +159.59% | +202.15% |
| Average volume | 793.28K | 3.14M |
| Shares outstanding | 96.04M | 299.36M |
| Employees | 393 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed SANA by 59.3 percentage points over the past year.
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
MGTX vs SANA FAQ
Which is bigger, MeiraGTx or Sana Biotechnology?
MeiraGTx (MGTX) is larger, with a market capitalization of $1.03B compared with $835.22M for Sana Biotechnology (SANA).
Which stock has performed better over the past year, MGTX or SANA?
MGTX returned +22.03% over the past 12 months, compared with -37.30% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are MeiraGTx and Sana Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.